Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 23, 2009 - Issue 18
492
Views
41
CrossRef citations to date
0
Altmetric
Original Articles

In vitro cytotoxic effects of Senecio stabianus Lacaita (Asteraceae) on human cancer cell lines

, , , , , , & show all
Pages 1707-1718 | Received 21 Apr 2008, Accepted 03 May 2008, Published online: 17 Nov 2009
 

Abstract

This study is aimed to evaluate the in vitro cytotoxicity of Senecio stabianus Lacaita (Asteraceae) against renal adenocarcinoma ACHN, hormone-dependent prostate carcinoma LNCaP, amelanotic melanoma C32 and human breast adenocarcinoma MCF-7 cell lines. The n-hexane extract showed an interesting activity with IC50 values of 62.7 and 71.1 μg mL−1 against C32 and LNCaP, respectively. Two compounds identified in the n-hexane extract, linalool and β-caryophyllene, were found to be active against C32 cells (IC50 values of 23.2 and 20.1 μg mL−1, respectively). Among tested constituents, the highest activity was found when α-humulene was applied to LNCaP cells (IC50 of 11.2 μg mL−1). In order to complete the phytochemical study on S. stabianus, which has not been investigated previously, the most characteristic secondary metabolites of Senecio genus, pyrrolizidine alkaloids (PAs), were analysed. Here we report the isolation, structural elucidation and identification of nine PAs.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.